NovaSight Reports Significant Long-Term Vision Improvements with CureSight Treatment

NovaSight, a company specializing in pediatric eyecare, announced study findings published in the American Journal of Ophthalmology showcasing the efficacy of its CureSight system for treating amblyopia, commonly known as lazy eye. The study revealed that children undergoing CureSight’s short-term binocular treatment experienced substantial improvements in visual and stereoacuity, which were sustained for at least a year. This marks the first large-scale randomized controlled trial to demonstrate a digital device’s effectiveness as non-inferior to traditional patching treatments.

Out of the initial participants treated with CureSight, follow-ups at 12-weeks and one year post-treatment confirmed the durability of vision gains, with statistically significant improvements maintained. CureSight, being FDA-cleared and CE-marked, offers a user-friendly, at-home digital treatment option that leverages eye-tracking technology to enhance visual acuity and stereoacuity while children watch their preferred content.

Following FDA clearance in October 2022, NovaSight had a successful early adoption of CureSight in the U.S., supported by over 250 eye care providers and resulting in more than 650 patient referrals. The company is poised for a comprehensive commercial launch in the U.S., Europe, and China in 2024, backed by significant investments from a healthcare-focused venture capital firm.